CO6480995A2 - Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv - Google Patents

Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Info

Publication number
CO6480995A2
CO6480995A2 CO12001297A CO12001297A CO6480995A2 CO 6480995 A2 CO6480995 A2 CO 6480995A2 CO 12001297 A CO12001297 A CO 12001297A CO 12001297 A CO12001297 A CO 12001297A CO 6480995 A2 CO6480995 A2 CO 6480995A2
Authority
CO
Colombia
Prior art keywords
hpv
prevention
human
pailoma
virus
Prior art date
Application number
CO12001297A
Other languages
English (en)
Inventor
Guy Jean Marie Fernand Pierre Baudox
Brigitte Desiree Alberte Colau
Najoua Dendouga
Sandra Giannini
Nicolas Pierre Fernand Lecrenier
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of CO6480995A2 publication Critical patent/CO6480995A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La divulgación proporciona construcciones novedosas de proteína del virus de papiloma humano (HPV) y su uso en la prevención de la enfermedad por el HPV. Las construcciones son proteínas quiméricas que comprenden proteínas L1 con un péptido L2 de HPV insertado en la proteína L1. Estas proteínas quiméricas se pueden formular en composiciones inmunogénicas, por ejemplo, de vacuna, y se pueden formular opcionalmente con las vacunas basadas en HPV L1 VLP.
CO12001297A 2009-06-25 2012-01-04 Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv CO6480995A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22035809P 2009-06-25 2009-06-25
US23988009P 2009-09-04 2009-09-04
US32210210P 2010-04-08 2010-04-08

Publications (1)

Publication Number Publication Date
CO6480995A2 true CO6480995A2 (es) 2012-07-16

Family

ID=43014491

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12001297A CO6480995A2 (es) 2009-06-25 2012-01-04 Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv

Country Status (20)

Country Link
US (1) US20120087937A1 (es)
EP (1) EP2445525A2 (es)
JP (1) JP2012530505A (es)
KR (1) KR20120098580A (es)
CN (1) CN102497880A (es)
AU (1) AU2010264695A1 (es)
BR (1) BRPI1014718A2 (es)
CA (1) CA2768172A1 (es)
CL (1) CL2011003271A1 (es)
CO (1) CO6480995A2 (es)
CR (1) CR20120026A (es)
DO (1) DOP2011000396A (es)
EA (1) EA022213B1 (es)
IL (1) IL217094A0 (es)
MA (1) MA33440B1 (es)
MX (1) MX2011013744A (es)
PE (1) PE20120563A1 (es)
SG (1) SG177269A1 (es)
WO (1) WO2010149752A2 (es)
ZA (1) ZA201109453B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
US9771397B2 (en) * 2011-12-01 2017-09-26 University Of Cape Town HPV chimaeric particle
EP2827891A1 (en) 2012-03-18 2015-01-28 GlaxoSmithKline Biologicals S.A. Method of vaccination against human papillomavirus
CN103864936B (zh) * 2012-12-11 2018-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv18型l2ne7e6融合蛋白基因、表达载体、方法、菌株和用途
WO2014103608A1 (ja) * 2012-12-25 2014-07-03 一般財団法人化学及血清療法研究所 HPV/HBsキメラタンパク質を有効成分とするHPV感染症及び／又はＢ型肝炎用ワクチン
CN104845985B (zh) * 2014-02-18 2020-02-07 上海泽润生物科技有限公司 重组人乳头瘤病毒蛋白表达
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
EP3209676A4 (en) * 2014-10-24 2018-03-28 Hpvvax, Llc Cancer and skin lesion treatment
DK3368068T3 (da) 2015-10-30 2021-02-22 Univ Copenhagen Viruslignende partikler med effektiv epitopdisplay
US10940194B2 (en) 2015-12-04 2021-03-09 Xiamen University Mutant of L1 protein of human papillomavirus type 58
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax Llc métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica
CN107188967B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
CN107188966B (zh) * 2016-03-15 2020-03-31 中国医学科学院基础医学研究所 一种乳头瘤病毒嵌合蛋白及其用途
KR102567627B1 (ko) * 2017-07-14 2023-08-17 시아먼 유니버시티 인간 유두종 바이러스 타입 16의 l1 단백질의 변이체
JP7290258B2 (ja) * 2018-09-26 2023-06-13 厦▲門▼大学 ヒトパピローマウイルス５１型のｌ１タンパク質の変異型
WO2021013077A1 (zh) * 2019-07-19 2021-01-28 神州细胞工程有限公司 嵌合的人乳头瘤病毒58型l1蛋白
CN114127099B (zh) * 2019-07-19 2024-04-19 神州细胞工程有限公司 嵌合的人乳头瘤病毒6型l1蛋白
CN114127097A (zh) * 2019-07-19 2022-03-01 神州细胞工程有限公司 嵌合的人乳头瘤病毒56型l1蛋白
CN111944834A (zh) * 2020-09-04 2020-11-17 吉林医药学院 人乳头瘤病毒16型表位嵌合l1的重组载体、重组蛋白、病毒样颗粒及其制备和应用
CN112300290B (zh) * 2020-09-30 2022-04-01 北京康乐卫士生物技术股份有限公司 一种使用乳头瘤病毒类病毒颗粒递呈抗原的新型冠状病毒多肽疫苗
CN114716562B (zh) * 2021-01-04 2023-11-10 中国医学科学院基础医学研究所 一种人乳头瘤病毒58型嵌合蛋白及其用途
CN114716561B (zh) * 2021-01-04 2024-03-12 中国医学科学院基础医学研究所 一种人乳头瘤病毒31型嵌合蛋白及其用途
CN114716560B (zh) * 2021-01-04 2024-02-02 中国医学科学院基础医学研究所 一种人乳头瘤病毒18型嵌合蛋白及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL117459A (en) * 1995-03-22 2005-11-20 Merck & Co Inc Dna encoding human papillomavirus type 18
US7351533B2 (en) 1997-09-05 2008-04-01 Medimmune, Inc. In vitro method for disassmbly/reassembly of papillomavirus virus-like particles (VLPs). Homogeneous VLP and cavsomere compositions produced by said methods: use thereof as vehicle for improved purification, and delivery of active agents
DK1015561T3 (da) 1997-09-05 2006-11-13 Medimmune Inc In vitro-fremgangsmåde til adskillelse/gensamling af papillomavirus-lignende partikler (VLP'er)
EP1012348B1 (en) 1997-09-16 2002-06-12 Innogenetics N.V. Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2003014402A2 (en) 2001-08-08 2003-02-20 Glaxosmithkline Biologicals S.A. Method for identification of type specific polynucleotide sequences
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7407807B2 (en) 2002-05-17 2008-08-05 University Of Cape Town Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
GB0228715D0 (en) 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
AU2006210792B2 (en) 2005-02-01 2012-07-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
JP4825958B2 (ja) * 2005-08-10 2011-11-30 財団法人ヒューマンサイエンス振興財団 高リスク群ヒトパピローマウイルスの中和抗体を誘導する抗原
KR20150090285A (ko) 2007-06-26 2015-08-05 고에키자이단호진 휴먼 사이언스 신코우자이단 고리스크군 인간 파필로마 바이러스에 대한 교차성 중화 항체를 유도하는 백신 항원
CA2704455C (en) * 2007-11-02 2020-09-01 Richard B. S. Roden Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
PT2318042E (pt) 2008-07-31 2014-11-05 Glaxosmithkline Biolog Sa Vacina contra hpv

Also Published As

Publication number Publication date
US20120087937A1 (en) 2012-04-12
WO2010149752A3 (en) 2011-03-31
SG177269A1 (en) 2012-02-28
PE20120563A1 (es) 2012-05-17
CN102497880A (zh) 2012-06-13
CA2768172A1 (en) 2010-12-29
MX2011013744A (es) 2012-09-28
EA201190327A1 (ru) 2012-07-30
DOP2011000396A (es) 2012-02-15
KR20120098580A (ko) 2012-09-05
AU2010264695A1 (en) 2012-01-19
EP2445525A2 (en) 2012-05-02
EA022213B1 (ru) 2015-11-30
ZA201109453B (en) 2012-08-29
CR20120026A (es) 2012-04-13
BRPI1014718A2 (pt) 2016-04-12
CL2011003271A1 (es) 2012-08-31
WO2010149752A2 (en) 2010-12-29
MA33440B1 (fr) 2012-07-03
JP2012530505A (ja) 2012-12-06
IL217094A0 (en) 2012-02-29

Similar Documents

Publication Publication Date Title
CO6480995A2 (es) Construcciones novedosas de proteina del virus de pailoma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
PH12018501602A1 (en) Subunit immersion vaccines for fish
CO2017004838A2 (es) Vacunas terapéuticas contra el vph16
TW200732476A (en) Functional influenza virus like particles (VLPs)
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
EA201391515A1 (ru) Инактивированная вакцина вируса денге
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
WO2008103819A3 (en) Chimeric newcastle disease virus vlps
PH12015501378B1 (en) Porcine parvovirus 5a, methods of use and vaccine
PH12017500450A1 (en) Flavivirus virus like particle
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
PH12015502666B1 (en) Dengue virus vaccine compositions and methods of use thereof
MX2015013304A (es) Vacunas de nucleoproteina de la influenza.
WO2014140166A3 (en) Vaccine
CL2017001595A1 (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas
MX2017008087A (es) Virus de la viruela porcina recombinante y vacunas.
AR115070A1 (es) Células madre que comprenden un virus vacuna quimérico sintético y métodos para su uso
MX360449B (es) Vacunas para el virus del papiloma humano y metodos para su uso.
EP2632942A4 (en) RECOMBINANT ENVELOPE PROTEIN OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) AND VACCINE CONTAINING THE SAME
PE20142102A1 (es) Metodos y composiciones para tratar enfermedades virales
AR109734A1 (es) Composiciones y métodos de tratamiento de la infección persistente por el virus del papiloma humano (hpv)
EA200702077A1 (ru) Вакцина
EA201892488A1 (ru) Комбинации лечебных вакцин против впч
PE20160940A1 (es) Newcastle recombinante expresando las proteinas s del virus de bronquitis aviar y sus aplicaciones